Companies

Description

Zoetis is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total revenue. Contemporaneous with the spinoff in June 2013 S&P Dow Jones Indices announced that Zoetis would replace First Horizon National Corporation in the S&P 500 stock market index.

History

1950s to 2000s

In the 1950s, Pfizer began research on several drugs, including oxytetracycline, which was found to be effective in livestock. In 1952, the Pfizer Agriculture Division opened a 732-acre research and development facility in Terre Haute, Indiana, called Vigo. By 1988 the division was renamed Pfizer Animal Health.

The 1995 acquisition of Norden Laboratories from GlaxoSmithKline expanded Pfizer's animal health division into small animal care, including domestic pets. Secondary research and development centres were opened in Kalamazoo, Michigan, in 2003. In the same year, Pfizer acquired Pharmacia Corporation for US$60 billion in stock options. Between 2007 and 2011, the company acquired Embrex Inc, Catapult Genetics, Bovigen, Wyeth, Fort Dodge Animal Health, Vetnex Animal Health Ltd, Synbiotics Corporation, Microtek, King Pharmaceuticals, and Alpharma.

 
2010s to present

Plans to break away Pfizer Animal Health into a separate company were officially announced in 2012. The new firm was named Zoetis in allusion to the Latin-derived zoological term zoetic, meaning "pertaining to life".

Zoetis Inc.'s revenues exceeded $4.2 billion in 2011 and $4.34 billion in 2012. The animal health industry worldwide is an estimated US$22 billion industry.

On May 22, 2013, The Wall Street Journal reported that Pfizer planned to sell its majority stake in the company. According to the report, shareholders will have the option to swap their Pfizer shares for Zoetis shares. The sell-off of Zoetis is consistent with Pfizer's recent decision to shed other non-pharmaceuticals subsidiaries in an effort to save costs, raise capital, and pay off debt. The company has announced that JPMorgan Chase, Bank of America, Merrill Lynch, Goldman Sachs & Co., and Morgan Stanley will be the lead underwriters.

In November 2014, activist investor Bill Ackman disclosed that Pershing Square Capital Management had taken an 8.5% stake in the company, amassing approximately 41.8 million shares, causing the share price to hit its highest price since the IPO. On 17 November, the company announced it would acquire a portfolio of pet drugs from Abbott Laboratories for approximately $255 million.

2012: IPO

Records show that Pfizer officially filed for registration of a Class A stock with the U.S. Securities and Exchange Commission on August 10, 2012. Zoetis' IPO on February 1, 2013 sold 86.1 million shares for US$ 2.2 billion.] Shares sharply rose 19% by the end of the trading day to $35.01 a share, up from $26. At the time, it was the largest IPO from a U.S. company since Facebook's $16 billion IPO on May 18, 2012. Pfizer retained 414 million Class B shares giving it an 83% controlling stake in the firm. Stock investors were attracted to the steep profit margin in proportion to revenue and consumer confidence in potential future growth of the subsidiary. The offering's lead underwriters were JPMorgan Chase, Bank of America Merrill Lynch and Morgan Stanley. Most of the money raised through the IPO was used to pay off existing Pfizer debt.

Acquisitions

In November 2015, the company announced it would acquire a developer of aquaculture treatments and diseases, Pharmaq, for $765 million. In 2017, Zoetis acquired Ireland-based Nexvet, a company with a biologics focused technology and product candidate pipeline.

In May 2018, the company announced its intention to acquire Abaxis for $1.9 billion in cash.

In August 2021, Zoetis announced it would buy Jurox, increasing the business' presence in New Zealand, the US, Canada and the UK.

Rating GlobalNY.biz

Take place
general
№3372
general
Take place
area
№347
In rating
Healthcare
area

Mentions in the news

View all

NEW YORK COMPANIES


New York business portal GlobalNY.biz includes a huge directory of organizations operating in New York. Here you can easily find all the necessary information about the company. The organization card contains a full info page with a detailed description of the company's activities, logo, contact details and a link to the organization's official website. The reader can also immediately familiarize himself with the staff of the company, see the latest press releases and news block, and also see what line of the rating the company occupies. The rating of a member of the GlobalNY.biz business portal is calculated based on the number of mentions in the New York news and posted press releases containing information about the organization's activities and its achievements. You can also rise in the rating by publishing vacancies, as well as the number of registered persons. At the same time, company representatives can independently see how many times the company's card has been viewed on GlobalNY.biz, as well as promptly correct the information.
We pay special attention to the multifunctionality of the "Companies" section. For your convenience, there is a search box, as well as an industry heading.
New York Business Portal is always up-to-date database of New York enterprises!
Alena Potapova

Development Director
Population
8173135708
Died this year
55688886
Born this year
137004516